S-1/A: CAMP4 Therapeutics Eyes Nasdaq Listing with $75 Million IPO

CAMP4 Therapeutics is seeking to raise capital through an initial public offering to advance its regulatory RNA-based therapeutics pipeline.

Summary

• CAMP4 Therapeutics is planning an initial public offering of 5,000,000 shares of common stock.
• The expected price range for the IPO is between $14.00 and $16.00 per share.
• The company is pursuing a Nasdaq Global Market listing under the symbol 'CAMP'.
• CAMP4 intends to use the IPO proceeds to advance its CMP-CPS-001 clinical development, CMP-SYNGAP program, expand its RAP Platform, and for general corporate purposes.
• The company's lead product candidate, CMP-CPS-001, is in Phase 1 clinical trials for urea cycle disorders, with data expected in 2025.
• CMP-SYNGAP, a preclinical program for SYNGAP1-related disorders, is expected to enter GLP toxicology studies in 2025.
• The FDA has granted Rare Pediatric Disease and Orphan Drug designations to CMP-CPS-001.
• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.
• CAMP4's investor group includes 5AM Ventures, AH Bio Fund I, L.P., Everest Aggregator, LP, Kaiser Permanente Group Trust, Northpond Ventures, LLC, Polaris Partners, and SMRS-TOPE LLC.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. The company has promising technology and programs, but it also faces significant financial challenges and risks. The sentiment is neutral to slightly positive.

Positives

• CMP-CPS-001 has received Rare Pediatric Disease and Orphan Drug designations from the FDA.
• Preclinical studies have demonstrated that CMP-CPS-001 can upregulate the production of multiple enzymes responsible for converting ammonia into urea.
• The company's RAP Platform has the potential to identify the regRNA associated with all of these diseases, which we believe enables us to design RNA Actuators to address the underlying biology of these diseases.

Negatives

• The company has incurred significant losses since its inception and expects to continue incurring losses for the foreseeable future.
• The company's approach to the discovery and development of product candidates based on its RAP Platform is unproven.
• The company is early in its development efforts and its lead product candidate is only in a Phase 1 clinical trial.

Risks

• The company may require substantial additional capital to finance its operations.
• The company's business is highly dependent on its lead product candidate, CMP-CPS-001.
• Drug development is a lengthy and expensive process, and preclinical and clinical testing is uncertain as to the outcome.
• If any of the company's product candidates cause undesirable side effects or have other unexpected adverse properties, such side effects or properties could delay or prevent regulatory approval.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before the company or more successfully than the company does.
• The company may enter into collaborations with third parties for the research, development and commercialization of certain of the product candidates the company may develop. If any such collaborations are not successful, the company may not be able to capitalize on the market potential of those product candidates.
• The company's future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel.
• The company may encounter difficulties in managing its growth and expanding its operations successfully.
• The company currently depends on third-party suppliers for the manufacture of its product candidates. The loss of these or future third-party suppliers, or their inability to provide the company with sufficient supply, could harm the company's business.
• The company's rights to develop and commercialize its product candidates are subject, in part, to the terms and conditions of licenses granted to the company by third parties. If the company fails to comply with its obligations under these arrangements or otherwise experience disruptions to its business relationships with its current or any future licensors, the company could lose such intellectual property rights that are important to its business.
• Third parties may initiate legal proceedings alleging that the company is infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm the company's business.
• If the company or its licensors are unable to obtain, maintain, enforce and adequately protect its intellectual property rights with respect to its product candidates and technology, or if the scope of any patent or other intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize products and technology similar or identical to ours, and its ability to successfully develop and commercialize its product candidates and technology may be adversely affected.
• The company relies, and intends to continue to rely, on third parties to perform some of its preclinical studies and conduct its clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements, or do not meet expected deadlines, its development programs may be delayed or subject to increased costs or the company may be unable to obtain regulatory approval for or commercialize its product candidates.
• There has been no public market for the company's common stock. An active, liquid, and orderly market for its common stock may not develop, or the company may in the future fail to satisfy the continued listing requirements of Nasdaq, and investors may not be able to resell their common stock at or above the initial public offering price or at all.
• The trading price of the shares of the company's common stock could be highly volatile, and purchasers of its common stock could incur substantial losses.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues the research and development of, and seeks regulatory approvals for, its lead product candidate CMP-CPS-001 for the treatment of urea cycle disorders, along with any other current or future product candidates it may develop.

Management Comments

• The company's mission has been to decode the rules of human gene expression to develop a new class of medicines that can transform the treatment paradigm for a wide range of genetic-based diseases.
• The company leverages its proprietary RAP Platform to map cells and discover regRNAs that regulate protein-coding genes in diseases characterized by sub-optimal levels of protein expression where modest increases in protein production can have a clinically meaningful therapeutic effect on patients.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous companies and institutions pursuing the development of new drug products. CAMP4 faces competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.

Comparison to Industry Standards

• The document mentions competitors such as Amgen, Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics Holdings Inc., iECure, Stoke Therapeutics, Inc. and Praxis Precision Medicines, Inc.
• Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals Inc. are listed as companies engaged in the commercialization and development of antisense oligonucleotides as therapeutics.
• Carbaglu, approved for ultra-rare N-acetylglutamate synthesase, or NAGS-deficient patients, utilized the URT in healthy volunteers and showed that minimal increases in ureagenesis translated to substantial ammonia reductions in NAGS-deficient patients.

Related Party Transactions

• In March 2021, we entered into a preferred stock purchase agreement with certain investors, including certain members of our board of directors, beneficial owners of greater than 5% of our capital stock and affiliates of members of our board of directors, pursuant to which we issued and sold an aggregate of 212,264,148 shares of our Series A Prime convertible preferred stock at a purchase price of $0.2120 per share for aggregate gross proceeds of $45.0 million.
• In June 2022, we entered into a preferred stock purchase agreement with certain investors, including beneficial owners of greater than 5% of our capital stock, affiliates of members of our board of directors and certain of our executive officers, pursuant to which we issued and sold to such investors an aggregate of 68,258,635 shares of our Series B convertible preferred stock at a purchase price of $1.4724 per share for aggregate gross proceeds of $100.5 million.
• In August 2021, we entered into a secured promissory note, or the Mandel-Brehm Promissory Note, with Josh Mandel-Brehm, our Chief Executive Officer, pursuant to which we loaned to Mr. Mandel-Brehm $565,999.96 to fund the payment associated with the early exercise of options held by Mr. Mandel-Brehm for 267,500 shares of Common Stock.
• In August 2021, we entered into a secured promissory note, or the Gold Promissory Note, with Kelly Gold, our Chief Financial Officer, pursuant to which we loaned to Ms. Gold $127,999.82 to fund the payment associated with the early exercise of options held by Ms. Gold for 60,494 shares of Common Stock.
• In August 2021, we entered into a secured promissory note, or the Bumcrot Promissory Note, with David Bumcrot, our Chief Scientific Officer, pursuant to which we loaned to Mr. Bumcrot $127,999.82 to fund the payment associated with the early exercise of options held by Ms. Bumcrot for 60,494 shares of Common Stock.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• Employees may benefit from the company's growth and success.
• Patients with UCDs and SYNGAP1-related disorders may benefit from the development of new therapies.
• The company's suppliers and partners may benefit from increased business opportunities.

Next Steps

• Report Phase 1 clinical trial data from all four cohorts of the SAD portion in the first quarter of 2025.
• Report Phase 1 clinical trial data from the MAD portion in the second half of 2025.
• Initiate final GLP toxicology studies in the SYNGAP1 program in 2025 to enable the filing of clinical trial applications.

Key Dates

Keywords

regulatory RNA, therapeutics, gene expression, urea cycle disorders, CMP-CPS-001, IPO, SYNGAP1, RAP Platform, clinical trials, biopharmaceutical